Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 32,878,926 | 51,639,109 | 61,556,925 | 53,970,524 | 81,695,780 | 281,741,264 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 32,878,926 | 51,639,109 | 61,556,925 | 53,970,524 | 81,695,780 | 281,741,264 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 97,345,673 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 184,395,591 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 32,878,926 | 51,639,109 | 61,556,925 | 53,970,524 | 81,695,780 | 281,741,264 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 3,205,975 | 3,312,682 | 4,952,174 | 5,045,294 | 6,808,320 | 23,324,445 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 38,049 | 742,082 | 258,491 | 19,731 | 13,394 | 1,071,747 |
| 11 | Total support. Add lines 7 through 10 | 306,137,456 | |||||
Calendar year (or fiscal
year beginning in) ![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2023 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2023 |
(iii) Distributable Amount for 2023 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2023 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2023 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2023: | ||||
| a From 2018....... | ||||
| b From 2019....... | ||||
| c From 2020....... | ||||
| d From 2021....... | ||||
| e From 2022....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2023 distributable amount | ||||
|
i
Carryover from 2018 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2023 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2023 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2023, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2023. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2024. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2019..... | ||||
| b Excess from 2020..... | ||||
| c Excess from 2021..... | ||||
| d Excess from 2022..... | ||||
| e Excess from 2023..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
| Return Reference | Explanation |
|---|---|
| FORM 990, PART I, LINE 1 & PART III, LINE 1: | THE NEW YORK GENOME CENTER (NYGC) IS AN INDEPENDENT NON-PROFIT SCIENTIFIC RESEARCH INSTITUTION DEDICATED TO COLLABORATIVE GENETIC AND GENOMIC RESEARCH. NYGC'S MISSION IS TO ADVANCE GENOMIC SCIENCE, AND THROUGH ITS APPLICATION, TO DRIVE NOVEL BIOMEDICAL DISCOVERIES. NYGC'S AREAS OF FOCUS INCLUDE THE DEVELOPMENT OF COMPUTATIONAL AND EXPERIMENTAL GENOMIC METHODS AND DISEASE-FOCUSED RESEARCH TO BETTER UNDERSTAND THE GENETIC BASIS OF CANCER, NEURODEGENERATIVE DISEASE AND NEUROPSYCHIATRIC DISEASE. THE NYGC TEAM, LED BY EVNIN FAMILY SCIENTIFIC DIRECTOR AND CEO TOM MANIATIS, PHD, INCLUDES ASSOCIATE AND CORE FACULTY MEMBERS WHO HOLD JOINT APPOINTMENTS AT LEADING ACADEMIC INSTITUTIONS. THE CENTER BRINGS TOGETHER OUTSTANDING THOUGHT LEADERS FROM TEN FOUNDING & THREE ASSOCIATE MEMBER INSTITUTIONS, AND 96 AFFILIATE SCIENTIFIC MEMBERS TO ENGAGE IN COLLABORATIVE RESEARCH. CONVENING TALENT AND EXPERTISE FROM MULTIPLE TOP-TIER SCIENTIFIC AND MEDICAL INSTITUTIONS IN THE NEW YORK AREA AND BEYOND, WE HAVE CREATED A HIGHLY COLLABORATIVE SCIENTIFIC ECOSYSTEM AND COMMUNITY RESOURCE THAT IS MORE THAN THE SUM OF ITS PARTS. NYGC ALSO PROVIDES RESEARCHERS WITH ACCESS TO STATE-OF-THE-ART GENOMIC INFRASTRUCTURE (E.G., COMPUTER HARDWARE AND SOFTWARE, SEQUENCING INSTRUMENTS) AND TECHNOLOGY INNOVATION AND EXPERTISE. NYGC HAS THE FOLLOWING KEY OBJECTIVES: (I) LEADING AND CONTRIBUTING TO INTELLECTUALLY VIBRANT RESEARCH COLLABORATIONS IN THE ACADEMIC AND SCIENTIFIC COMMUNITY IN NEW YORK CITY, ACROSS THE COUNTRY AND AROUND THE WORLD. (II) RECRUITING AND RETAINING DIVERSE WORLD-CLASS SCIENTIFIC TALENT TO LEAD THE ORGANIZATION'S RESEARCH AND TECHNOLOGY DEVELOPMENT PROGRAMS; (III) SUPPORTING RESEARCH CONDUCTED BY THE INSTITUTIONAL FOUNDING MEMBERS, OTHER ACADEMIC, RESEARCH AND MEDICAL INSTITUTIONS AND THE BIOTECHNOLOGY/PHARMACEUTICAL INDUSTRY TO ADVANCE NYGC'S SCIENTIFIC RESEARCH MISSION; (IV) DEVELOPING INNOVATIVE EXPERIMENTAL AND COMPUTATIONAL GENOMIC METHODS BASED UPON THE RESEARCH AND SEQUENCING ACTIVITIES CONDUCTED AT THE ORGANIZATION'S FACILITY, FOR THE BROADER BENEFIT OF THE RESEARCH COMMUNITY; (V) IMPROVING HUMAN HEALTH THROUGH GENOMIC RESEARCH THAT DRIVES NOVEL BIOMEDICAL DISCOVERIES; (VI) STRIVING TO MAXIMIZE THE BENEFITS OF OUR RESEARCH AND INNOVATION FOR DIVERSE COMMUNITIES; (VII) PROVIDING TRAINING TO THE ACADEMIC, RESEARCH AND TECHNOLOGY COMMUNITIES; (VIII) CREATING A WORKPLACE ENVIRONMENT THAT IS WELCOMING AND FAIR TO ALL REGARDLESS OF RACE, ETHNICITY, GENDER, SEXUAL ORIENTATION, PHYSICAL DISABILITY, AGE, OR RELIGION, AND (IX) CONDUCTING ACTIVITIES ANCILLARY TO THESE OBJECTIVES. NYGC STRIVES TO CHAMPION DIVERSITY, EQUITY, AND INCLUSION IN ITS WORKPLACE AND IN THE APPLICATION OF ITS RESEARCH TO CLINICAL CARE. A FUNDAMENTAL GOAL OF THE GENOME CENTER IS ADDRESSING THE LACK OF DIVERSITY WITHIN DATA, SAMPLES, AND SUBJECTS IN GENOMICS RESEARCH. NYGC IS ALSO COMMITTED TO DIVERSITY ON THE CENTER'S BOARD OF DIRECTORS AND WITHIN ITS FACULTY, STAFF, AND SCIENTIFIC RESEARCHERS. |
| FORM 990, PART III, LINE 4A & LINE 4B | NEUROPSYCHIATRIC DISEASE: THE NEW YORK GENOME CENTER IS BUILDING A NEUROPSYCHIATRIC DISEASE RESEARCH PROGRAM AIMED AT INVESTIGATING THE MECHANISMS UNDERLYING NEUROPSYCHIATRIC AND NEURODEVELOPMENTAL DISORDERS, SUCH AS SCHIZOPHRENIA, BIPOLAR DISORDER, AND AUTISM SPECTRUM DISORDER. NYGC'S VISION ENCOMPASSES A MULTI-LAYERED APPROACH, INTEGRATING VARIOUS LEVELS OF ANALYSIS TO ADVANCE OUR UNDERSTANDING OF THE BIOLOGICAL UNDERPINNINGS OF NEUROPSYCHIATRIC DISORDERS. THIS INCLUDES DELINEATING THE GENETIC AND PHENOTYPIC ARCHITECTURE OF THESE DISORDERS IN DIVERSE POPULATIONS AND PERFORMING FUNCTIONAL STUDIES TO UNRAVEL THEIR UNDERLYING BIOLOGY, USING DIVERSE MODEL SYSTEMS. NYGC IN PARTNERSHIP WITH INSTITUTIONAL FOUNDING MEMBERS WILL BUILD A TRANSLATIONAL PLATFORM FOR PRECISION PSYCHIATRY DEDICATED TO PROVIDING PATIENTS WITH ACCESS TO EVIDENCE-BASED MENTAL HEALTH CARE, WITH SPECIAL EMPHASIS ON DATA SECURITY AND PATIENT PRIVACY. AN NYGC SIGNATURE PROJECT IN NEUROPSYCHIATRIC DISEASE RESEARCH IS THE GENOMIC MEDICINE FOR MENTAL HEALTH ADVANCEMENT (GEMMA) INITIATIVE, WHICH AIMS TO DEVELOP A PATIENT-CENTRIC PLATFORM FOR PRECISION PSYCHIATRY. GEMMA , A COLLABORATION BETWEEN THE NYGC, COLUMBIA UNIVERSITY, NORTHWELL HEALTH, AND THE NEW YORK STATE OFFICE OF MENTAL HEALTH WILL BE DEDICATED TO PROVIDING PATIENTS WITH ACCESS TO EVIDENCE BASED MENTAL HEALTH CARE AND THE INTEGRATION OF GENETIC AND CLINICAL RECORDS INTO PROGNOSIS, AND CLINICAL CARE. THE PLATFORM"S INITIAL TARGET POPULATION ARE THE HISTORICALLY UNDERSERVED POPULATIONS OF THE NEW YORK STATE MENTAL HEALTH SYSTEM. BEGINNING IN 2023, NYGC TOGETHER WITH THE BROAD INSTITUTE OF MIT AND HARVARD, AND THE UNIVERSITY OF CALIFORNIA, LOS ANGELES, WILL COLLABORATE TO CREATE THE BD GENETICS PLATFORM. THIS PLATFORM WILL BE USED TO PERFORM GENOMIC PROFILING OF ONE OF THE MOST DIVERSE POPULATIONS OF PEOPLE WITH BIPOLAR DISORDER, INCLUDING MORE THAN 30,000 STUDY SUBJECTS FROM AFRICA, CENTRAL AMERICA, SOUTH AMERICA, AND ASIA. ADDITIONALLY, NYGC IS ADVANCING ITS CLINICAL OUTCOME PREDICTION OF PSYCHOSIS FROM ELECTRONIC HEALTH RECORDS (COPPER), A PILOT STUDY LEVERAGING THE GEMMA PLATFORM FOCUSED ON ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING, TO BUILD MODELS OF CLINICAL PREDICTORS OF DIAGNOSIS, TREATMENT, AND PROGNOSIS OF PSYCHOSIS-RELATED DISORDERS. IN PRECISION PSYCHIATRY, THE NYGC TEAM PLANS TO INTEGRATE LARGE-SCALE LONGITUDINAL ELECTRONIC HEALTH RECORDS, DIMENSIONAL PHENOTYPING, AND GENETIC ANALYSES TO IMPROVE CLINICAL PREDICTORS OF SERIOUS MENTAL ILLNESS. BEGINNING IN 2023, DR. LEHNER AND ASSOCIATE FACULTY MEMBER, DR. TARJINDER SINGH, LAUNCHED A NEW PROJECT TO CARRY OUT WHOLE GENOME SEQUENCING AND BIOINFORMATIC ANALYSIS ON A WELL-CHARACTERIZED COHORT OF PATIENTS WITH SEVERE SCHIZOPHRENIA. IN COLLABORATION WITH DR. CARLOS PATO AT RUTGERS UNIVERSITY AND LEVERAGING NEW REDUCED-COST SEQUENCING PLATFORMS, NYGC WILL SEQUENCE AND ANALYZE A COHORT OF 2,500 PATIENTS WITH SEVERE SCHIZOPHRENIA FROM THE RUTGERS GENOMIC PSYCHIATRY COHORT TO IDENTIFY POTENTIALLY CAUSATIVE GENETIC VARIANTS. RESEARCHERS WILL ALSO BE ABLE TO USE CELL LINES DERIVED FROM EACH PARTICIPANT IN THE COHORT TO INVESTIGATE THE UNDERLYING CAUSATIVE DISEASE MECHANISMS. THE RESEARCH TEAM PLANS TO INTEGRATE THE WHOLE GENOME SEQUENCE DATA WITH EXISTING LARGE-SCALE DATASETS, CONTROLS, AND INTERNATIONAL DISCOVERY EFFORTS TO ADVANCE PRECISION MEDICINE IN PSYCHIATRY. GENOMIC TECHNOLOGY: NYGC'S TECHNOLOGY INNOVATION LAB HAS POSITIONED THE CENTER AT THE LEADING EDGE OF GENOMIC TECHNOLOGY INNOVATION, ALLOWING FOR DEEPER FUNCTIONAL STUDIES OF DISEASE BIOLOGY WITH INCREASING RESOLUTION AND BROADER ACCESSIBILITY FOR THE RESEARCH COMMUNITY. THESE INCLUDE THE DEVELOPMENT OF HIGH-THROUGHPUT TECHNOLOGIES FOR SIMULTANEOUS MEASUREMENT OF PROTEINS, RNA, AND CHROMATIN STRUCTURE AT SPATIAL RESOLUTIONS AT OR BELOW THE SINGLE CELL LEVEL, ALONG WITH SOPHISTICATED COMPUTATIONAL AND STATISTICAL TOOLS TO FURTHER THE ANALYSIS OF MULTI-MODAL GENOMICS. THE TECHNOLOGY INNOVATION LAB IS ACTIVELY INVOLVED IN ADVANCING SPATIALLY-RESOLVED SINGLE CELL TECHNOLOGIES, WHICH CAN SIMULTANEOUSLY MAP THE ACTIVITIES OF TENS OF THOUSANDS OF GENES ACROSS TISSUE SECTIONS. THE LAB PLAYED A PIVOTAL ROLE IN THE INVENTION OF SPATIAL TRANSCRIPTOMICS (ST), A GROUNDBREAKING METHOD THAT WAS NAMED METHOD OF THE YEAR IN 2020, EMPOWERING RESEARCHERS TO UNRAVEL THE COMPLEXITIES OF DISEASE GENERATION WITH UNPRECEDENTED RESOLUTION. THIS YEAR, THE TECHNOLOGY INNOVATION LAB HAS BEEN WORKING TO PUSH THE BOUNDARIES OF CURRENT ST TECHNIQUES TO ADVANCE THE TECHNOLOGY AND ITS APPLICATION. AS A RESULT, THE LAB HAS PIONEERED A NOVEL ST TECHNOLOGY EMPLOYING SIMPLE MICROFLUIDICS AND 3D PRINTABLE TOOLING TO CREATE GLASS SLIDES WITH SPATIALLY BARCODED REGIONS FOR INCREASED SPATIAL RESOLUTION, CONTINUOUS AND EFFICIENT CAPTURING, AND A LARGE FIELD OF VIEW, BROADENING THE UTILITY AND APPLICATIONS OF ST. THIS NEW METHOD MAINTAINS COST-EFFECTIVENESS AND ALLOWS FOR EASY CUSTOMIZATION ENABLING BROADER ADOPTION WITHIN THE SCIENTIFIC COMMUNITY. IN GENOMICS RESEARCH, THERE HAS ALSO BEEN A SIGNIFICANT BREAKTHROUGH AND INCREASED FOCUS ON OPTICAL MULTI-OMICS (OMO) TECHNOLOGIES THAT CAN MEASURE THE ACTIVITY OR ABUNDANCE OF RNA AND PROTEIN SIMULTANEOUSLY AND AT SINGLE-CELL RESOLUTION WITHIN INTACT TISSUES. THE TECHNOLOGY INNOVATION LAB HAS DEVELOPED AN OPEN-SOURCE CODE BASE AND CONSUMABLE DESIGN SET, TO REPURPOSE RETIRED HIGH-END DNA SEQUENCERS INTO OMO HARDWARE THAT IS EQUIVALENT TO COMMERCIAL PLATFORMS. THIS INNOVATIVE AND COST-EFFECTIVE SOLUTION ALLOWS RESEARCHERS TO GO FROM TISSUE TO ANALYZED DATA IN A MATTER OF DAYS OR EVEN HOURS, OVERCOMING FINANCIAL AND LEGAL CONSTRAINTS ASSOCIATED WITH COMMERCIAL OMO SOLUTIONS. THE TECHNOLOGY INNOVATION LAB HAS BEEN WORKING TO DEVELOP COMPANION COMPUTATIONAL APPROACHES ENABLING SPATIAL MODELING OF SUCH HIGHLY COMPLEX DATA ACROSS LARGE COHORTS OF TISSUE SAMPLES AND INDIVIDUALS, PROVIDING A COMPREHENSIVE UNDERSTANDING OF THE IMPACT OF DISEASE AND AGING ON VARIOUS ORGANS, FROM THE BRAIN TO THE LARGE INTESTINE. |
| FORM 990, PART III, LINE 4A & LINE 4B (CONTINUED) | CLINICAL LABORATORY: NYGC'S CLINICAL LABORATORY CONTINUES TO LEVERAGE ITS INFRASTRUCTURE AND EXPERTISE FOR SEVERAL LARGE-SCALE INITIATIVES IN CLINICAL GENOMICS, INCLUDING A COLLABORATION WITH WEILL CORNELL MEDICINE, NEWYORK-PRESBYTERIAN HOSPITAL ON A PRECISION MEDICINE INITIATIVE FOCUSED ON CANCER, CARDIOLOGY, ENDOCRINOLOGY, AND NEUROLOGY. THE AIM IS TO ENHANCE THE VALUE OF CLINICAL WHOLE GENOMES, RETURN CLINICALLY ACTIONABLE RESULTS, AND GAIN A DEEPER UNDERSTANDING OF THE ROLE OF GENETICS IN THERAPEUTIC RESPONSES. THE FINDINGS FROM THESE EFFORTS HAVE BEEN PRESENTED AT THE ACMG MEETING, AND NYGC PLANS TO CONTINUE UPDATING ITS PANELS TO INCORPORATE NEW GENETIC INSIGHTS ANNUALLY. THE CLINICAL LABORATORY HAS INITIATED A COLLABORATION WITH THE DEPARTMENT OF OBSTETRICS AND GYNECOLOGY AT COLUMBIA UNIVERSITY, ESTABLISHING THE WOMEN'S GENETICS CENTER (WGC). THIS CENTER LEVERAGES THE COMBINED STRENGTHS OF COLUMBIA'S MATERNAL-FETAL MEDICINE PHYSICIANS AND GENETIC COUNSELORS, ALONG WITH TNYGC'S LEADING EXPERTISE IN TECHNOLOGY AND CLINICAL GENETICS. THE WGC IS DEDICATED TO DEVELOPING AND IMPLEMENTING NOVEL CLINICAL TESTS TO IMPROVE CARE FOR PREGNANT WOMEN. TO DATE, THE CLINICAL LABORATORY HAS PERFORMED OVER 1,200 WHOLE-GENOME SEQUENCING (WGS) PRENATAL TESTS TO IDENTIFY GENETIC CAUSES OF ANOMALIES DETECTED VIA ULTRASOUND IN SUPPORT OF THIS EFFORT. ADDITIONALLY, PLANS ARE UNDERWAY TO DEVELOP MORE INNOVATIVE WHOLE-GENOME-BASED TESTS THAT WILL BENEFIT ROUTINE PRENATAL DIAGNOSIS, INCLUDING FOR NON-ANOMALOUS CASES. THESE EFFORTS AIM TO DEMONSTRATE THE VALUE OF PRENATAL GENETIC SEQUENCING (GS) FOR ANOMALIES, STILLBIRTH, AND ROUTINE PRENATAL DIAGNOSIS. THE WGC AIMS TO ESTABLISH ITSELF AS A NATIONAL AND INTERNATIONAL LEADER IN FETAL GENOMICS AND PRECISION MEDICINE BY BUILDING THE NECESSARY DATA FOR OBTAINING REIMBURSEMENT FOR CLINICAL GS TESTS. FURTHERMORE, THE WGC IS COMMITTED TO DELIVERING INNOVATIVE HEALTHCARE SOLUTIONS TAILORED TO PATIENTS OF DIVERSE RACIAL, ETHNIC, AND SOCIOECONOMIC BACKGROUNDS, ULTIMATELY DEMONSTRATING THE BROAD BENEFITS OF CLINICAL GS TO THE WIDER COMMUNITY. NYGC HAS BEEN CHOSEN AS A CLINICAL SITE FOR THE IHOPE GENETIC HEALTH INITIATIVE, A NEWLY LAUNCHED PRO BONO GENETIC TESTING PROGRAM. THIS INITIATIVE AIMS TO CREATE A GLOBAL NETWORK OF LABORATORIES AND CLINICAL SITES TO PROVIDE GENETIC TESTING FOR UNDIAGNOSED CHILDREN FROM UNDER-RESOURCED COMMUNITIES. NYGC IS ONE OF ONLY THREE SEQUENCING LABS WORLDWIDE, AND THE ONLY ONE IN THE UNITED STATES, SELECTED TO PARTICIPATE IN THE INITIAL PHASE. THANKS TO SUCCESSFUL FUNDRAISING EFFORTS AT NYGC, WE HAVE SECURED SUPPORT TO PROVIDE GENETIC TESTING FOR 85 PATIENTS THROUGH THIS PROGRAM. RESEARCH SEQUENCING: NYGC HAS ONE OF THE LARGEST VOLUME WHOLE GENOME SEQUENCING PROGRAMS IN NEW YORK. IN THE PAST TEN YEARS, NYGC'S SEQUENCING LABORATORY HAS SEQUENCED OVER 102,800 WHOLE GENOME SAMPLES. NYGC HAS ACQUIRED TWO OF THE NEWEST ILLUMINA NOVASEQ X SYSTEMS SEQUENCERS, EACH WITH THE CAPACITY TO SEQUENCE TWENTY THOUSAND HUMAN GENOMES ANNUALLY. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREAT SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. IN ADDITION, NYGC OPERATES AN OXFORD NANOPORE PROMETHION SEQUENCER FOR LONG READ SEQUENCING, AND CONTINUED TO TEST AND VALIDATE A HIGH-THROUGHPUT SEQUENCER FROM ULTIMA GENOMICS (THE UG100). NYGC'S RESEARCH SEQUENCING LAB, LED BY SOREN GERMER, PHD, SENIOR VICE PRESIDENT OF GENOME TECHNOLOGIES, PROCESSED MORE THAN 28,000 SAMPLES IN 2023, INCLUDING 4,226 WHOLE GENOME SEQUENCING SAMPLES (GERMLINE AND CANCER), AND 18,182 TRANSCRIPTOME (RNA) SEQUENCING SAMPLES. IN 2023, NYGC CONTINUED TO FOCUS ITS OPERATIONAL EFFORTS ON SINGLE CELL MULTI-OMICS, EXPANDING THE SCOPE OF APPLICATION FOR CUTTING-EDGE TECHNIQUES AVAILABLE TO THE RESEARCH COMMUNITY, INCLUDING CITE-SEQ, ECCITE-SEQ, SINGLE-NUCLEUS RNA-SEQ, DOGMA-SEQ, SINGLE-CELL LONG READ RNA AND ATAC-SEQ AND THE 10X MULTIOME ASSAY, THROUGH FUNCTIONAL GENOMIC COLLABORATIONS ACROSS MULTIPLE TISSUE TYPES AND DISEASES. THESE TECHNIQUES ALLOW SIMULTANEOUS MEASUREMENT IN THOUSANDS OF CELLS COMBINATIONS OF CELL SURFACE PROTEIN MARKERS, T-CELL AND B-CELL ANTIGEN RECEPTORS, RNA ABUNDANCE AND CHROMATIN ACCESSIBILITY INCREASING SCALE THROUGH HASHING WHICH ENABLES SAMPLE MULTIPLEXING. THE CENTER'S TECHNOLOGY DEVELOPMENT LABORATORY HAS COMPLETED SEVERAL PROJECTS IN WHICH THESE ASSAYS HAVE BEEN APPLIED SUPPORTING RESEARCH IN SCHIZOPHRENIA AND ALZHEIMER'S DISEASES FROM INDUCED PLURIPOTENT STEM DIFFERENTIATED CNS CELLS AND BRAIN TISSUE. THE LAB IS ALSO ACTIVELY SUPPORTING MULTIPLE LARGE-SCALE GRANTS INCLUDING SINGLE NUCLEUS TRANSCRIPTOME PROFILING OF POSTMORTEM SPINAL CORD OF AMYOTROPHIC LATERAL SCLEROSIS PATIENTS IN COLLABORATION WITH COLUMBIA UNIVERSITY; MULTI-OMICS MAPS OF HUMAN ENDOMETRIUM IN DIVERSE ANCESTRIES IN COLLABORATION WITH COLD SPRING HARBOR LABORATORY, NORTHWELL HEALTH AND WEILL CORNELL MEDICAL CENTER; AND THE STUDY OF THE INITIATION OF DIFFUSE AND INTESTINAL NON-CARDIA GASTRIC CANCER IN COLLABORATION WITH COLUMBIA UNIVERSITY. IN ADDITION, THE LAB CONTINUES TO SUPPORT A LARGE STUDY OF ESOPHAGEAL CANCER IN COLLABORATION WITH COLUMBIA UNIVERSITY AND CAMBRIDGE UNIVERSITY UTILIZING A NOVEL AMPLIFICATION FREE SINGLE CELL WHOLE GENOME SEQUENCING ASSAY. DIVERSITY, EQUITY, AND INCLUSION: IN 2020, NYGC LAUNCHED AN ORGANIZATION-WIDE DIVERSITY, EQUITY, AND INCLUSION ("DEI") INITIATIVE, AFFIRMING NYGC'S COMMITMENT TO TAKE ACTIONABLE STEPS TOWARD FOSTERING A COMMUNITY ENVIRONMENT THAT IS WELCOMING AND INCLUSIVE TO ALL. EACH EMPLOYEE HAS THE RIGHT TO BE TREATED WITH DIGNITY AND RESPECT OF INDIVIDUAL DIFFERENCES. IN 2023, NYGC'S CROSS-FUNCTIONAL DEI ADVISORY GROUP PROVIDED EDUCATION AND RESOURCES TO THE NYGC COMMUNITY TO RAISE AWARENESS OF DEI AND TO ENHANCE CULTURAL COMPETENCY, SUCH AS BOOK CLUBS, SHOWCASING THE WORK AND SKILLS OF A DIVERSE GROUP OF EMPLOYEES, STAFF, FACULTY AND TRAINEES, AND ORGANIZED DEI-RELATED EVENTS. THE CENTER HIRED A NEW DIRECTOR OF DEI TO SPEARHEAD EXISTING AND EXPANDED DEI EFFORTS. THE DIRECTOR LAUNCHED A DIVERSITY, EQUITY & INCLUSION IMPACT AWARD AND INITIATED PLANNING FOR AN INAUGURAL POST BACCALAUREATE EARLY CAREER DEVELOPMENT TRAINING PROGRAM. |
| FORM 990, PART III, LINE 4A & LINE 4B | THE NEW YORK GENOME CENTER (NYGC) IS COMMITTED TO ADVANCING GENOMIC SCIENCE, AND THROUGH ITS APPLICATION, TO DRIVING THE DEVELOPMENT OF NOVEL BIOMEDICAL THERAPEUTICS FOR CLINICAL CARE. RESEARCH AND FACULTY CENTRAL TO THE SUCCESS OF NYGC IS OUR TALENTED FACULTY WHO POSE FUNDAMENTAL QUESTIONS, DEVELOP NOVEL APPROACHES TO SCIENTIFIC INQUIRY, AND DEEPLY PROBE THE BIOLOGICAL MECHANISMS RELEVANT TO HUMAN HEALTH AND DISEASE. THE GENOMIC EXPERTISE OF OUR WORLD-CLASS SCIENTISTS INCLUDES CANCER, NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISEASE, GENOME EDITING, SINGLE-CELL AND SPATIALLY-RESOLVED MULTIOMICS, HIGH-RESOLUTION IMAGING, 3-DIMENSIONAL GENOME STRUCTURE, FUNCTIONAL GENOMICS, WHOLE GENOME SEQUENCING, BIOINFORMATICS, COMPUTATIONAL BIOLOGY, MACHINE LEARNING, GENOMIC DATA PRIVACY, AND MOLECULAR DIAGNOSTICS. EACH FACULTY MEMBER HAS BUILT A ROBUST RESEARCH PROGRAM AND HOLDS A JOINT TENURE-TRACK APPOINTMENT AT ONE OF OUR PARTNER INSTITUTIONS. NYGC ALSO HAS A DISTINGUISHED GROUP OF SENIOR ASSOCIATE FACULTY AND SCIENTIFIC ADVISORY BOARD (SAB) WHO ARE ESTABLISHED LEADERS IN GENOMICS AND BRING INVALUABLE SCIENTIFIC LEADERSHIP AND MENTORSHIP TO THE CENTER. OUR SENIOR LEADERSHIP TEAM, TOGETHER WITH THE EXTENSIVE EXPERIENCE AND GUIDANCE OF OUR SENIOR FACULTY AND SAB, EMPOWERS THE NEXT GENERATION OF GENOMIC RESEARCHERS TO INNOVATE AND DRIVE BREAKTHROUGHS IN BIOMEDICAL RESEARCH. IN 2023, WE EXPANDED THE EXPERTISE OF OUR ASSOCIATE FACULTY, A STRATEGIC STEP FORWARD. WITH THESE APPOINTMENTS, WE ADDED DEPTH, BREADTH, AND SCOPE TO THE GENOM\E CENTER'S OVERALL RESEARCH PROGRAM. THE NEW MEMBERS INCLUDE: STEPHAN SANDERS, PHD, BMBS, ALSO HOLDS JOINT APPOINTMENTS AS A PROFESSOR OF PEDIATRIC NEUROGENETICS IN THE DEPARTMENT OF PEDIATRICS AT THE UNIVERSITY OF OXFORD AND AS A MEMBER OF THE FACULTY AT THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO. DR. SANDERS' RESEARCH FOCUSES ON USING GENE DISCOVERY, FUNCTIONAL GENOMICS, AND BIOINFORMATICS TO UNDERSTAND THE ETIOLOGY OF NEURODEVELOPMENTAL DISORDERS. IN ADDITION TO THEIR APPOINTMENTS AS ETHNICITY AND CANCER SCHOLARS FOR NYGC'S POLYETHNIC-1000 (P-1000) PROGRAM, ONYINYE BALOGUN, MD AND MELISSA DAVIS, PHD HAVE ACCEPTED ASSOCIATE FACULTY APPOINTMENTS AT THE GENOME CENTER. ONYINYE BALOGUN, MD HOLDS A JOINT APPOINTMENT AS ASSISTANT PROFESSOR OF RADIATION ONCOLOGY AT WEILL CORNELL MEDICINE SPECIALIZING IN THE TREATMENT OF BREAST AND GYNECOLOGIC MALIGNANCIES. DR. BALOGUN HAS CONDUCTED AND PUBLISHED BREAST CANCER RESEARCH IN NOVEL THERAPEUTICS FOR TRIPLE NEGATIVE BREAST CANCER AND BRAIN METASTASES. MELISSA DAVIS, PHD HOLDS JOINT APPOINTMENTS AS DIRECTOR OF THE INSTITUTE OF TRANSLATIONAL GENOMIC MEDICINE AND INTERIM ASSOCIATE PROFESSOR OF MICROBIOLOGY BIOCHEMISTRY AND IMMUNOLOGY AT MOREHOUSE SCHOOL OF MEDICINE (MSM) AND ASSOCIATE ADJUNCT PROFESSOR OF DEVELOPMENT AND CELL BIOLOGY, SCIENTIFIC DIRECTOR, INTERNATIONAL CENTER FOR THE STUDY OF BREAST CANCER SUBTYPES, INTERIM DIRECTOR OF HEALTH EQUITY AT THE ENGLANDER INSTITUTE OF PRECISION MEDICINE AT WEILL CORNELL MEDICINE (WCM). DR. DAVIS' RESEARCH FOCUSES ON IDENTIFYING BIOLOGICAL MECHANISMS OF RACIAL DISPARITIES IN CANCER RISK AND CLINICAL OUTCOMES OF CANCER DIAGNOSES. DR. DAVIS HAS JOINED NYGC'S MACMILLAN CSNCG AS A CO-PI, AND IS WORKING WITH NYGC AND INTERNATIONAL COLLABORATORS TO LEAD A CANCER GRAND CHALLENGES (JOINTLY FUNDED BY CANCER RESEARCH UK AND THE NIH NATIONAL CANCER INSTITUTE) PROJECT TEAM FOR SOCIETAL, ANCESTRY, MOLECULAR AND BIOLOGICAL ANALYSES OF INEQUALITIES (SAMBAI). IN 2023, NYGC SCIENTISTS PUBLISHED 69 STUDIES IN HIGH-IMPACT SCIENTIFIC JOURNALS ESTABLISHING NEW INSIGHTS INTO THE CAUSES AND MECHANISMS OF DISEASE, INNOVATIVE NEW GENOMIC TECHNOLOGIES, AND NOVEL COMPUTATIONAL APPROACHES THAT WE SHARE WIDELY WITH THE SCIENTIFIC COMMUNITY TO HELP ADVANCE PRECISION MEDICINE. AT THE CLOSE OF 2023, TWO CORE FACULTY MEMBERS, RAHUL SATIJA, PHD, AND NEVILLE SANJANA, PHD, WERE NAMED AMONG THE WORLD'S MOST CITED RESEARCHERS ON CLARIVATE ANALYTICS' 2023 HIGHLY CITED RESEARCHERS LIST FOR THE FIFTH CONSECUTIVE YEAR. THIS ANNUAL LIST GATHERS THOSE IN THE FIELD WHO DEMONSTRATED SIGNIFICANT AND BROAD INFLUENCE REFLECTED IN THEIR PUBLICATIONS OF MULTIPLE HIGHLY CITED PAPERS OVER THE LAST DECADE. THE HIGHLY CITED PAPERS RANK IN THE TOP 1% BY CITATION FOR A FIELD OR FIELDS AND PUBLICATION YEAR IN THE WEB OF SCIENCE. IN 2023, NYGC FACULTY AND SCIENTISTS WERE THE RECIPIENTS OF SEVERAL PRESTIGIOUS AND COMPETITIVE GRANTS SUPPORTING VARIOUS ASPECTS OF THE CENTER'S PIONEERING RESEARCH. SELECT AWARDS INCLUDE: THE CENTER FOR NEUROPSYCHIATRIC DISEASE, LED BY DR. THOMAS LEHNER, NYGC'S SCIENTIFIC DIRECTOR FOR NEUROPSYCHIATRIC DISEASE, RECEIVED TWO GRANTS IN SEPARATE ROUNDS OF FUNDING FROM BD: BREAKTHROUGH DISCOVERIES FOR THRIVING WITH BIPOLAR DISORDER. THE FIRST GRANT TOTALING $15M WAS AWARDED TO THE NYGC ALONG WITH THE BROAD INSTITUTE OF MIT AND HARVARD, AND THE UNIVERSITY OF CALIFORNIA, LOS ANGELES (UCLA) TO SUPPORT THE CREATION OF THE BD GENETICS PLATFORM. THIS COLLABORATIVE EFFORT WILL PERFORM GENETIC SEQUENCING ON ONE OF THE LARGEST AND MOST DIVERSE POPULATIONS OF PEOPLE WITH BIPOLAR DISORDER, INCLUDING MORE THAN 30,000 STUDY SUBJECTS FROM AFRICA, CENTRAL AMERICA, SOUTH AMERICA AND ASIA. IN COLLABORATION WITH RUTGERS UNIVERSITY AND COLUMBIA UNIVERSITY, A SECOND GRANT FROM BD WAS ANNOUNCED LATER IN THE YEAR, NAMING NYGC AS A RECIPIENT OF A THREE-YEAR $4.5M GRANT TO SUPPORT RESEARCH AIMED AT FURTHER UNDERSTANDING THE BIOLOGICAL PROCESSES UNDERLYING BIPOLAR DISORDER. THE CENTER'S COMMITMENT TO COLLABORATIVE SCIENCE WAS ALSO RECOGNIZED THROUGH A TWO-YEAR TARGET ALS GRANT AWARDED TO HEMALI PHATNANI, PHD, CORE FACULTY MEMBER AND DIRECTOR OF THE CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE (CGND) AND SANJA VICKOVIC, PHD, CORE FACULTY MEMBER AND DIRECTOR OF THE TECHNOLOGY INNOVATION LAB. THEIR MULTI-YEAR GRANT SUPPORTS THE PROJECT "CREATING A SPATIAL GENOMICS RESOURCE FOR AMYOTROPHIC LATERAL SCLEROSIS-FRONTOTEMPORAL DEMENTIA (ALS-FTD) NEUROPATHIES." THIS PROJECT WILL ADDRESS THE MOLECULAR MECHANISMS DRIVING DIVERSE ALS-FTD CAUSES. IN OCTOBER OF 2023, CHENXU ZHU, PHD, WHO HOLDS A JOINT APPOINTMENT AS AN NYGC CORE FACULTY MEMBER AND ASSISTANT PROFESSOR IN THE DEPARTMENT OF PHYSIOLOGY AND BIOPHYSICS AND THE INSTITUTE FOR COMPUTATIONAL BIOMEDICINE AT WEILL CORNELL MEDICINE, WAS AWARDED THE NATIONAL INSTITUTES OF HEALTH (NIH) DIRECTOR'S NEW INNOVATOR AWARD. DR. ZHU MARKS THE FOURTH NYGC CORE FACULTY MEMBER TO RECEIVE THE NIH DIRECTOR'S NEW INNOVATOR AWARD. NYGC IS THE RECIPIENT OF THE NIH COMMON FUND SOMATIC MOSAICISM ACROSS HUMAN TISSUES (SMAHT) NETWORK. THE AWARDED GRANTS OF $140 MILLION OVER FIVE YEARS FUND TWO RESEARCH PROJECTS LED BY SOREN GERMER, PHD, VICE PRESIDENT OF GENOME TECHNOLOGIES, SAM APARICIO, BM, BCH, PHD, FRCPATH, FRSC, SENIOR SCIENTIFIC DIRECTOR OF CANCER GENOMICS, DAN LANDAU, MD, PHD, NYGC CORE FACULTY MEMBER AND ASSOCIATE PROFESSOR OF MEDICINE IN THE DIVISION OF HEMATOLOGY AND MEDICAL ONCOLOGY AT WEILL CORNELL MEDICINE, AND RAHUL SATIJA, PHD, NYGC CORE FACULTY MEMBER AND ASSOCIATE PROFESSOR OF BIOLOGY AT NEW YORK UNIVERSITY. NYGC'S THOMAS LEHNER, PHD, MPH, GAMZE GRSOY, PHD, MIKE ZODY, PHD, CHARLES GAGNON, AND SHAILU GARGEYA RECEIVED AN AWARD FROM THE WARREN ALPERT FOUNDATION IN SUPPORT OF THE GENOMIC MEDICINE FOR MENTAL HEALTH ADVANCEMENT (GEMMA) DATA COMMONS PROJECT WHICH WILL SERVE AS A UNIQUE PLATFORM TO IMPLEMENT CLINICAL PREDICTION ALGORITHMS, THERAPEUTIC DISCOVERY EFFORTS, AND DATA-DRIVEN CLINICAL TRIAL ENROLLMENT. NYGC MADE GREAT PROGRESS IN CORE RESEARCH AREAS UNDER THE LEADERSHIP OF THE NEW YORK GENOME CENTER'S EVNIN FAMILY SCIENTIFIC DIRECTOR AND CEO, TOM MANIATIS, PHD. SELECT ACHIEVEMENTS INCLUDE: CANCER: EARLY IN 2023, NYGC LAUNCHED THE MACMILLAN CENTER FOR THE STUDY OF THE NON-CODING CANCER GENOME (CSNCG), A GROUNDBREAKING MULTI-DISCIPLINARY COLLABORATION BRINGING 23 INVESTIGATORS AND NINE INSTITUTIONS TOGETHER TO DEVELOP TECHNOLOGIES AND UNDERTAKE STUDIES AIMED AT UNDERSTANDING THE STRUCTURE AND FUNCTION OF THE NON-CODING GENOME AND EPIGENOME IN CANCER EVOLUTION, PROGRESSION, AND TREATMENT RESPONSE. THE MACMILLAN CENTER HAS A STRONG COMMITMENT TO OPEN SCIENCE AND COLLABORATION. ENABLED BY A GENEROUS LEAD GIFT FROM THE MACMILLAN FAMILY FOUNDATION, THE CSNCG HAS UNDERTAKEN THE GRAND CHALLENGE OF DECODING THE IMPACT OF THE NON-CODING GENOME IN CANCER BY CREATING AN END-TO-END DISCOVERY PLATFORM WITH EXPANSIVE RESEARCH EFFORTS, SPANNING FROM LARGE-SCALE MAPPING OF THE STRUCTURE AND FUNCTION OF DIVERSE CANCER GENOMES TO THE DEVELOPMENT OF NOVEL CELLULAR THERAPEUTICS AND DRUG DISCOVERY. THE CSNCG'S COLLABORATIVE APPROACH FOSTERS THE SHARING OF INFORMATION AND BREAKTHROUGHS WHICH POSITIONS THE CSNCG AS A CATALYST FOR TRANSFORMATIVE ADVANCEMENTS IN CANCER RESEARCH AND TREATMENT. |
| FORM 990, PART III, LINE 4A & LINE 4B (CONTINUED) | ADDITIONALLY, IN 2023, A WORLD-CLASS RESEARCH TEAM LED BY MELISSA B. DAVIS, PHD, NYGC ASSOCIATE FACULTY AND POLYETHNIC-1000 (P-1000) CANCER ETHNICITY SCHOLAR AND THE DIRECTOR OF THE INSTITUTE OF TRANSLATIONAL GENOMIC MEDICINE AT MOREHOUSE SCHOOL OF MEDICINE, WAS SELECTED AS ONE OF FIVE INTERNATIONAL RESEARCH TEAMS TO RECEIVE UP TO $25M IN FUNDING FROM CANCER GRAND CHALLENGES. WITH THESE FUNDS, THE SAMBAI (SOCIETAL, ANCESTRY, MOLECULAR, AND BIOLOGICAL ANALYSES OF INEQUALITIES) TEAM WILL ADDRESS THE ISSUE OF INEQUITIES IN CANCER PREVENTION, SCREENING, AND TREATMENT BY: FOCUSING ON PROSTATE, BREAST, AND PANCREATIC CANCERS IN DIVERSE COHORTS OF AFRICAN DESCENT FROM REGIONS WITHIN AFRICA, THE UNITED KINGDOM, AND THE UNITED STATES. BUILDING AN UNPRECEDENTED RESOURCE COMPRISED OF COMPREHENSIVE MEASUREMENTS OF SOCIAL, ENVIRONMENTAL, GENETIC, AND BIOLOGICAL FACTORS USED TO HELP DEFINE THE CAUSES OF DISPARATE OUTCOMES IN THE SELECTED POPULATIONS. THE TEAM UNITES CLINICIANS, ADVOCATES, AND SCIENTISTS ACROSS FIFTEEN INSTITUTIONS AND SEVEN COUNTRIES WITH BROAD EXPERTISE IN EPIDEMIOLOGY, EXPOSOMICS, GENOMICS, IMMUNOLOGY, AND COMPUTATIONAL BIOLOGY. DR. NICOLAS ROBINE, DIRECTOR OF COMPUTATIONAL BIOLOGY AT NYGC, AND DR. MARCIN IMIELISKI, CORE FACULTY MEMBER AT NYGC AND DIRECTOR OF CANCER GENOMICS AT NYU LANGONE HEALTH'S PERLMUTTER CANCER CENTER, ARE WORKING ALONGSIDE OTHER GENOMICS COLLABORATORS TO PROCESS AND CONTEXTUALIZE LARGE AND COMPLEX DATA USING NOVEL ALGORITHMS, CLOUD COMPUTING, AND GRAPH REPRESENTATIONS OF REFERENCE SEQUENCES, WHICH ARE WELL-SUITED TO ANALYZE GENOMIC DATA OF PARTICIPANTS FROM DIVERSE ANCESTRIES. NEURODEGENERATIVE DISEASE: THE CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE (CGND), LED BY NYGC CORE FACULTY MEMBER HEMALI PHATNANI, PHD, HAS ESTABLISHED A GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) CONSORTIUM, CONSISTING OF 42 MEMBER INSTITUTIONS WORLDWIDE. THE CGND HAS ALSO CONTRIBUTED TO ALS RESEARCH WITH THE DEVELOPMENT OF GENOMIC TECHNOLOGIES FOR THE STUDY OF RNA TRANSCRIPTION, SINGLE CELL TRANSCRIPTION, AND SPATIAL TRANSCRIPTOMICS. NYGC LEVERAGES THE SUCCESS OF OUR CGND'S FOCUS ON ALS RESEARCH TO EXTEND OUR WORK ACROSS A WIDER RANGE OF NEURODEGENERATIVE DISEASES THAT, DESPITE THEIR DIVERSE CLINICAL MANIFESTATIONS, SHARE COMMON PATHWAYS WITH ALS; SUCH DISEASES INCLUDE VASCULAR DEMENTIA, ALZHEIMER'S DISEASE, FRONTOTEMPORAL DEMENTIA (FTD), PARKINSON'S DISEASE, AND HUNTINGTON'S DISEASE. NYGC'S CGND RESEARCHERS HAVE BEEN WORKING WITH GLOBAL COLLABORATORS, UTILIZING NEW TECHNOLOGIES TO CREATE A MULTIDIMENSIONAL ATLAS OF GENE EXPRESSION IN ALS THAT PROVIDES NEW INSIGHTS INTO THE MECHANISMS THAT CONTRIBUTE TO DISEASE ONSET AND PROGRESSION. THESE BREAKTHROUGH FINDINGS ADVANCE THE UNDERSTANDING OF DISEASE MECHANISMS IN ALL NEURODEGENERATIVE DISEASES THAT SHARE COMMON PATHWAYS WITH ALS. NOTABLY, NYGC EVNIN FAMILY SCIENTIFIC DIRECTOR AND CEO, TOM MANIATIS AND NYGC CORE FACULTY MEMBER AND DIRECTOR OF THE NYGC'S CGND, HEMALI PHATNANI, HAVE BEEN WORKING CLOSELY WITH DAN DOCTOROFF AND TARGET ALS, ALONG WITH PARTNERS AT THE ALS ASSOCIATION GREATER NEW YORK CHAPTER, UNIVERSITY OF ROCHESTER MEDICAL CENTER, AND THE ELEANOR AND LOU GEHRIG ALS CENTER AT COLUMBIA UNIVERSITY TO ENCOURAGE NEW YORK STATE TO EXPAND SUPPORT FOR ALS RESEARCH IN NEW YORK. AS A RESULT OF THESE COLLABORATIVE EFFORTS, GOVERNOR HOCHUL RECENTLY ANNOUNCED A PLAN TO MAKE $25 MILLION IN STATE FUNDING AVAILABLE FOR ALS RESEARCH AND CARE - FUELING EARLY DIAGNOSIS EFFORTS, SCIENTIFIC STUDIES, AND DRUG DEVELOPMENT, AND PAVING THE WAY FOR MAJOR RESEARCH EFFORTS IN ALS, NEURODEGENERATIVE DISEASE, AND AGING IN NEW YORK STATE. |
| FORM 990, PART VI, SECTION A, LINE 2 | NYGC BOARD MEMBERS ELI CASDIN, ANTHONY EVNIN, THOMAS MANIATIS, JAMES SIMONS, AND NANCY THORNBERRY HAVE A BUSINESS RELATIONSHIP, EITHER DIRECTLY OR INDIRECTLY, THROUGH KALLYOPE, INC., A BIOTECHNOLOGY COMPANY DEVELOPING ORAL THERAPEUTICS AGAINST METABOLIC, NEUROLOGICAL, AND GASTROINTESTINAL DISEASES. NYGC HAS NOT CONDUCTED ANY BUSINESS WITH KALLYOPE, INC. |
| FORM 990, PART VI, SECTION A, LINE 6 | ORGANIZATION MEMBERS AS OF DECEMBER 31, 2023, THE CENTER HAD A TOTAL OF 13 MEMBERS, CONSISTING OF TEN INSTITUTIONAL FOUNDING MEMBERS AND THREE ASSOCIATE MEMBERS. THE INSTITUTIONAL FOUNDING MEMBERS ARE THE FOLLOWING RECOGNIZED ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS: (1) COLD SPRING HARBOR LABORATORY, (2) CORNELL UNIVERSITY/WEILL CORNELL MEDICINE, (3) MEMORIAL SLOAN-KETTERING CANCER CENTER, (4) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, (5) NEW YORK-PRESBYTERIAN HOSPITAL, (6) NEW YORK UNIVERSITY, SCHOOL OF MEDICINE, (7) NORTHWELL HEALTH, (8) THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, ON BEHALF OF STONY BROOK UNIVERSITY, (9) THE ROCKEFELLER UNIVERSITY, AND (10) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK. ASSOCIATE MEMBERS: (1) AMERICAN MUSEUM OF NATURAL HISTORY, (2) HOSPITAL FOR SPECIAL SURGERY, AND (3) HACKENSACK MERIDIAN HEALTH. |
| FORM 990, PART VI, SECTION A, LINE 7A | ORGANIZATION MEMBERS - DECISION MAKING EACH INSTITUTIONAL FOUNDING MEMBER APPOINTS ONE REPRESENTATIVE TO SERVE ON NYGC'S BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES THE SCIENTIFIC DIRECTOR/CEO AND INDEPENDENT DIRECTORS APPOINTED BY THE BOARD. DECISIONS REQUIRING BOARD APPROVAL INCLUDE THE ADMISSION OF NEW MEMBERS, CHANGES TO THE MISSION, CERTIFICATE OF INCORPORATION, AND BYLAWS, APPOINTMENT OR REMOVAL OF THE CHAIRPERSON OF THE BOARD AND THE SCIENTIFIC DIRECTOR, AND ADOPTION OF CERTAIN POLICIES AND PROCEDURES. THE BOARD ALSO REVIEWS AND APPROVES THE ANNUAL OPERATING BUDGET. MANAGEMENT HAS THE ABILITY TO ENTER INTO BUSINESS ARRANGEMENTS AND CONTRACTS, INCLUDING FINANCING ARRANGEMENTS AND HAS THE DISCRETION TO MAKE CERTAIN DECISIONS WITHOUT FORMAL BOARD APPROVAL |
| FORM 990, PART VI, SECTION B, LINE 11B | FORM 990 REVIEW THE FORM 990 IS PREPARED BY AN INDEPENDENT PUBLIC ACCOUNTING FIRM, UTILIZING INFORMATION PROVIDED BY MANAGEMENT. UPON RECEIPT OF THE DRAFT FORM 990, MANAGEMENT, INCLUDING THE CHIEF FINANCIAL OFFICER; DIRECTOR OF FINANCE; GENERAL COUNSEL; AND THE SCIENTIFIC DIRECTOR/CEO REVIEW THE FORM. PRIOR TO FILING, MANAGEMENT PRESENTS THE FORM 990 TO THE AUDIT COMMITTEE OF THE BOARD FOR REVIEW AND COMMENT. ALSO PRIOR TO FILING, MANAGEMENT PROVIDES THE FORM 990 TO THE ENTIRE BOARD OF DIRECTORS |
| FORM 990, PART VI, SECTION B, LINE 12C | CONFLICT OF INTEREST POLICY & REVIEW NYGC REQUIRES ALL INTERESTED PERSONS (DEFINED AS BOARD MEMBERS, OFFICERS, AND KEY EMPLOYEES) TO DISCLOSE CONFLICTS OF INTEREST AS REQUIRED BY THE CONFLICT OF INTEREST POLICY. NYGC FOLLOWS A PROCEDURE FOR OBTAINING SUCH DISCLOSURES ANNUALLY. ANY POTENTIAL CONFLICTS OF INTEREST DISCLOSED BY BOARD MEMBERS OR OFFICERS MUST BE REVIEWED BY THE BOARD. IF AN INTERESTED PERSON HAS A POTENTIAL CONFLICT OF INTEREST, HE OR SHE MAY PRESENT INFORMATION RELEVANT TO THE CONFLICT OF INTEREST OR UNDERLYING TRANSACTION AT A BOARD OR COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE/SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE TRANSACTION OR ARRANGEMENT THAT CREATES THE POTENTIAL CONFLICT OF INTEREST. |
| FORM 990, PART VI, SECTION B, LINE 15 | COMPENSATION REVIEW AND APPROVAL FFOR THE ORGANIZATION'S TOP MANAGEMENT OFFICIAL, PLEASE REFER TO SCHEDULE J NARRATIVES FOR THE PROCESS OF DETERMINING COMPENSATION. FOR 2023, NYGC HIRED AN INDEPENDENT, OUTSIDE COMPENSATION CONSULTANT TO PERFORM AN ANALYSIS OF SENIOR MANAGEMENT'S TOTAL COMPENSATION. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO MEMBERS OF SENIOR MANAGEMENT WAS REASONABLE. THE COMPENSATION COMMITTEE OF THE BOARD (WHICH IS COMPOSED OF INDEPENDENT BOARD MEMBERS) MET AT A COMMITTEE MEETING HELD IN JANUARY 2023 AND APPROVED THE 2023 COMPENSATION TO BE PAID TO SENIOR MANAGEMENT. THE COMMITTEE DOCUMENTED ITS ACTIONS IN WRITTEN MEETING MINUTES. THE SENIOR MANAGEMENT TEAM RECEIVED STANDARD MERIT INCREASES IN 2023. MARIA JOANTA RECEIVED A SALARY INCREASE IN 2023 TO BRING HER SALARY CLOSER TO MARKET LEVELS AT THE RECOMMENDATION OF AN INDEPENDENT COMPENSATION CONSULTANT WHO PERFORMED AN EXECUTIVE TOTAL COMPENSATION STUDY FOR NYGC. THIS SALARY CHANGE WAS REVIEWED BY A COMPENSATION COMMITTEE OF INDEPENDENT BOARD MEMBERS AND APPROVED BY THE BOARD OF DIRECTORS. |
| FORM 990, PART VI, SECTION C, LINE 19 | NYGC'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. |
| FORM 990, PART VII, SECTION A | IN 2023, TOM MANIATIS, PHD., SCIENTIFIC DIRECTOR & CEO, WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR AND CEO, AN OFFICER OF THE CORPORATION, AND AN ASSOCIATE MEMBER OF NYGC'S FACULTY, WITH RESPONSIBILITY FOR OVERSEEING NYGC'S RESEARCH PROGRAMS AND FOR UNDERTAKING SUCH OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. DR. MANIATIS DEVOTES 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINS A LABORATORY AND CONDUCTS INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS. |
| Software ID: | |
| Software Version: |